New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide

Biomarkers

Volumn 20, Issue 2, 2015, Pages 143-148

  Van Boxtel, W ^a,b   Bulten, B F ^b,c   Mavinkurve Groothuis, A M C ^b,d   Bellersen, L ^b   Mandigers, C M P W ^e   Joosten, L A B ^a   Kapusta, L ^b,f   De Geus Oei, L F ^b,c   Van Laarhoven, H W M ^a,g  

^a Department of Medical Oncology ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f Wolfson Medical Centre Holon   (Israel)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anthracyclines; Biological markers; Breast neoplasms; Echocardiography; Heart failure; Pro brain natriuretic peptide

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GALECTIN 3; INTERLEUKIN 6; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; ST2 BIOMARKER; TROPONIN I; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TAXOID; TUMOR NECROSIS FACTOR;

ADULT; AGED; AORTA VALVE STENOSIS; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER DIAGNOSIS; CARDIOTOXICITY; CHEMILUMINESCENCE IMMUNOASSAY; COHORT ANALYSIS; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ECHOCARDIOGRAPH; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIMIT OF DETECTION; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; R WAVE; TRANSTHORACIC ECHOCARDIOGRAPHY; ADOLESCENT; BLOOD; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; HEART; PATHOPHYSIOLOGY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS; BREAST NEOPLASMS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTIN 3; HEART; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; TAXOIDS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84934291719     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1040839     Document Type: Article

References (33)

1. Braunwald E. (2008). Biomarkers in heart failure. N Engl J Med 358: 2148-59.
2. Bristow MR, Mason JW, Billingham ME, Daniels JR. (1981). Doseeffect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709-18.
3. Cardinale D, Sandri MT, Colombo A, et al. (2004). Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-54.
4. Carrio I, Estorch M, Berna L, et al. (1995). Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36:2044-9.
5. Conklin KA. (2005). Coenzyme q10 for prevention of anthracyclineinduced cardiotoxicity. Integr Cancer Ther 4:110-30.
6. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. (2008). Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97:318-26.
7. Erkus B, Demirtas S, Yarpuzlu AA, et al. (2007). Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr 96:506-9.
8. Feola M, Garrone O, Occelli M, et al. (2011). Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 148:194-8.
9. Germanakis I, Kalmanti M, Parthenakis F, et al. (2006). Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 108:212-15.
10. Hess G, Runkel S, Zdunek D, Hitzler WE. (2005). Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): a study in blood donors. Clin Chim Acta 360:187-93.
11. Horacek JM, Pudil R, Jebavy L, et al. (2007). Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 29:309-13.
12. Horacek JM, Vasatova M, Tichy M, et al. (2010). The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 32:97-9.
13. Jensen BV, Skovsgaard T, Nielsen SL. (2002). Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13:699-709.
14. Kong SY, Lee HL, Eom HS, et al. (2008). Reference intervals for circulating angiogenic cytokines. Clin Chem Lab Med 46:545-50.
15. Koseoglu V, Berberoglu S, Karademir S, et al. (2005). Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin Turk J Pediatr 47:17-22
16. Ky B, French B, Levy WC, et al. (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 5:183-90.
17. Lang RM, Bierig M, Devereux RB, et al. (2005). Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-63.
18. Lipshultz SE, Colan SD, Gelber RD, et al. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-15.
19. Mantovani G, Madeddu C, Cadeddu C, et al. (2008). Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 13: 1296-305.
20. Martin M, Pienkowski T, Mackey J, et al. (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-13.
21. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, et al. (2009). Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 52:631-6.
22. Meinardi MT, Van der Graaf WT, Van Veldhuisen DJ, et al. (1999). Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25:237-47.
23. NABON. (2012). National guideline breast carcinoma. Available at: http://www.oncoline.nl/mammacarcinoom [last accessed 14 Nov 2014].
24. Romano S, Fratini S, Ricevuto E, et al. (2011). Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 105:1663-8.
25. Sawaya H, Sebag IA, Plana JC, et al. (2012). Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5:596-603.
26. Seta Y, Shan K, Bozkurt B, et al. (1996). Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243-9.
27. Shelburne N, Adhikari B, Brell J, et al. (2014). Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst 106:pii-dju232.
28. Soker M, Kervancioglu M. (2005). Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 26:1197-202.
29. Steinherz LJ, Steinherz PG, Tan CT, et al. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672-7.
30. Suzuki T, Hayashi D, Yamazaki T, et al. (1998). Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362-3.
31. Tallaj JA, Franco V, Rayburn BK, et al. (2005). Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24:2196-201.
32. Tang WH, Katz R, Brennan ML, et al. (2009). Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 103:1269-74.
33. Trudeau M, Charbonneau F, Gelmon K, et al. (2005). Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886-98.